CKPT — Checkpoint Therapeutics Share News
0.000.00%
Last trade - 00:00- $370.71m
- $337.66m
- $0.04m
Brief: Checkpoint Therapeutics Announces $7.5 Mln Registered Direct Offering
Advisory: Research alert on Checkpoint Therapeutics Inc withdrawn
Advisory: Stray alert on Checkpoint Software Technologies withdrawn
Checkpoint Therapeutics rises on seeking FDA approval for skin cancer drug
Brief: Checkpoint Therapeutics Submits Biologics License Application To FDA For Carcinoma Drug Cosibelimab
Brief: Checkpoint Therapeutics Announces Reverse Stock Split
Checkpoint Therapeutics down after reverse stock split plan
Brief: Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results
Checkpoint Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Checkpoint Therapeutics Reports Q2 2022 Results
Brief: Checkpoint Therapeutics Announces Positive Interim Results From Registration-Enabling Trial Of Cosibelimab In Locally Advanced Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Checkpoint Therapeutics Reports First Quarter 2022 Results
Checkpoint Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Checkpoint Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Checkpoint Reports 2021 Results, Recent Corporate Highlights
Checkpoint Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Checkpoint Therapeutics Announces Positive Topline Results From The Registration-Enabling Trial Of Cosibelimab In Metastatic Cutaneous Squamous Cell Carcinoma
Checkpoint jumps on positive data for skin cancer drug